Surface Oncology Stock Debt To Equity
Fundamental analysis of Surface Oncology allows traders to better anticipate movements in Surface Oncology's stock price by examining its financial health and performance throughout various phases of its business cycle.
Surface |
Surface Oncology Company Debt To Equity Analysis
Surface Oncology's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Surface Oncology Debt To Equity | 0.45 % |
Most of Surface Oncology's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Surface Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Surface Oncology has a Debt To Equity of 0.453%. This is 99.15% lower than that of the Biotechnology sector and 97.66% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.07% higher than that of the company.
Surface Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Surface Oncology's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Surface Oncology could also be used in its relative valuation, which is a method of valuing Surface Oncology by comparing valuation metrics of similar companies.Surface Oncology is currently under evaluation in debt to equity category among its peers.
Surface Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.41 | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 60.82 M | |||
| Shares Owned By Insiders | 7.27 % | |||
| Shares Owned By Institutions | 46.03 % | |||
| Number Of Shares Shorted | 165.27 K | |||
| Price To Earning | 0.64 X | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 30 M | |||
| Gross Profit | (37 M) | |||
| EBITDA | (61.87 M) | |||
| Net Income | (63.59 M) | |||
| Cash And Equivalents | 156.65 M | |||
| Cash Per Share | 2.70 X | |||
| Total Debt | 56.04 M | |||
| Debt To Equity | 0.45 % | |||
| Current Ratio | 8.19 X | |||
| Book Value Per Share | 0.81 X | |||
| Cash Flow From Operations | (59.55 M) | |||
| Short Ratio | 0.45 X | |||
| Earnings Per Share | (1.66) X | |||
| Target Price | 2.38 | |||
| Number Of Employees | 35 | |||
| Beta | 1.75 | |||
| Market Capitalization | 65.69 M | |||
| Total Asset | 159.91 M | |||
| Retained Earnings | (204.33 M) | |||
| Working Capital | 112.88 M | |||
| Current Asset | 22 K | |||
| Current Liabilities | 36 K | |||
| Z Score | -1.33 | |||
| Net Asset | 159.91 M |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Surface Stock
If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |